ImmunoBiochem enters a deal with ImmunoGen to develop next-generation antibody-drug conjugates

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

ImmunoBiochem recently announced a multi-target license and option agreement with ImmunoGen to advance novel, first-in-class antibody drug conjugates. The collaboration will combine ImmunoGen's proprietary linker and payload technologies with ImmunoBiochem's antibodies directed against specific targets.

ImmunoBiochem is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Retispec’s innovative AI technology transforming Alzheimer’s disease screening
Next

OBIO® receives funding from the Ontario government to bring new technologies to market